GeoVax Labs, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter ended September 30, 2023; comparisons are with the three and nine months ended September 30, 2022, and balance-sheet comparisons are with December 31, 2022. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies. Its clinical programs include GEO-CM04S1, a COVID-19 vaccine, and Gedeptin for advanced head and neck cancer; other vaccine and cancer programs are preclinical.
Key financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $81,526 |
| Research and development expense | $6.95 million | $2.72 million | $14.49 million | $5.36 million |
| General and administrative expense | $1.65 million | $1.25 million | $4.56 million | $3.36 million |
| Net loss | $8.41 million | $3.97 million | $18.37 million | $8.64 million |
| Basic and diluted loss per share | $0.32 | $0.17 | $0.69 | $0.63 |
| Operating cash used | Not separately stated for quarter | Not separately stated for quarter | $14.90 million | $11.97 million |
Balance sheet and liquidity: At September 30, 2023, cash and cash equivalents were $12.69 million, current assets $14.80 million, current liabilities $7.08 million, working capital $7.72 million, total assets $16.20 million, and stockholders’ equity $9.12 million. Cash declined $14.93 million from year-end 2022. No debt is reported on the presented balance sheet. Gross margin and operating margin are not meaningful to assess given the absence of product revenue.
Material changes and developments
- Q3 operating expenses rose $4.63 million year over year; nine-month expenses increased $10.33 million. Management attributed the increases mainly to clinical-trial and manufacturing costs, technology license fees, personnel, preclinical work, and related costs.
- Net loss increased $4.44 million in Q3 and $9.74 million for the first nine months versus 2022. The 2023 nine-month period had no grant revenue, following the wind-down of a U.S. Department of Defense Lassa Fever grant; all approved funds had been used by September 30.
- Interest income rose to $190,936 for Q3 and $674,835 for nine months, primarily reflecting cash available for investment and higher interest rates.
- GEO-CM04S1’s healthy-booster Phase 2 trial completed enrollment; its immunocompromised-patient Phase 2 trial expanded to additional sites, and a Phase 2 CLL trial began in July. Gedeptin interim trial data reported safety and feasibility, with tumor growth impairment observed in a majority of patients.
- GeoVax signed a commercial license for ProBioGen’s suspension cell line to support MVA vaccine manufacturing. It also reported patent allowances and a patent issuance related to vaccine technologies.
- Common shares outstanding were 26,695,287 at September 30, up from 26,334,953 at December 31, 2022. The company also reported 13,384,115 warrants outstanding and 2,018,800 options outstanding.
Outlook, risks, and contingencies
- Management estimated existing cash would fund planned operations only into the first quarter of 2024. The filing states that substantial additional funding is needed and that substantial doubt exists about the company’s ability to continue as a going concern within one year from issuance of the financial statements. Management expects to seek equity or debt financing, grants, partnerships, or other sources, but cannot assure availability or favorable terms.
- Without sufficient capital, GeoVax may have to delay, reduce, or discontinue development programs. Management expects continued losses and higher R&D spending as clinical programs advance; it does not provide cost or completion-time estimates.
- Nasdaq had granted an additional 180-day period, through December 4, 2023, to regain compliance with the $1.00 minimum bid-price requirement; failure could lead to delisting, subject to a possible appeal.
- Commitments include an office and laboratory lease expiring December 31, 2025, terminable by either party with 180 days’ notice, plus contingent license payments and generally cancellable clinical and manufacturing contracts. Legal proceedings: none reported. The company reported effective disclosure controls and no significant changes to internal control over financial reporting in the quarter.
Important facts for investors to verify
- Whether GeoVax obtained financing after the filing date and whether cash runway extended beyond the first quarter of 2024.
- Whether the company regained Nasdaq’s minimum bid-price compliance by December 4, 2023, or faced delisting proceedings.
- Enrollment, safety, efficacy, and timing updates for GEO-CM04S1 and Gedeptin, and the related clinical-trial and manufacturing cash requirements.
- Potential dilution and financing capacity, including the terms of the July 2023 at-the-market offering agreement and the outstanding warrants and options.
- The timing and amount of license fees, milestones, and other contractual obligations, which may depend on uncertain events.